Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan HVSEN Biotechnology is a prominent Chinese animal health company dedicated to the research, development, and manufacturing of veterinary pharmaceuticals and vaccines. Established in 2002, the company has built a significant market presence in the livestock industry, particularly focusing on swine health through its extensive range of anti-infective drugs and immunological products. HVSEN operates multiple GMP-certified production lines and maintains a strong R&D focus on fermentation technology and chemical synthesis. Publicly traded on the Shenzhen Stock Exchange, the company is expanding its portfolio to include poultry and pet health solutions to diversify its revenue streams.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhan HVSEN Biotechnology.